Cushing's Syndrome clinical trials at UCSF
1 research study open to eligible people
Showing trials for
(PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
open to eligible people ages 2-17
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
San Francisco, California and other locations
Our lead scientists for Cushing's Syndrome research studies include Maya Lodish.
Last updated: